Literature DB >> 8740869

Frequency of subclinical visceral leishmaniasis in HIV-1-infected patients in Spain.

J A Pineda, J Hernández-Quero, J A Gallardo, M A López-Ruz, M A Martínez-Pérez, J Macías, E Lissen.   

Abstract

Entities:  

Mesh：

Year:  1996        PMID： 8740869     DOI： 10.1007/bf01591371

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  7 in total

1.  Asymptomatic leishmaniasis in the acquired immunodeficiency syndrome (AIDS)

Authors:  M J Condom; B Clotet; G Sirera; F Milla; M Foz
Journal:  Ann Intern Med       Date:  1989-11-01       Impact factor: 25.391

2.  Activation of human immunodeficiency virus type 1 in monocytoid cells by the protozoan parasite Leishmania donovani.

Authors:  R Bernier; S J Turco; M Olivier; M Tremblay
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

3.  New perspectives on a subclinical form of visceral leishmaniasis.

Authors:  R Badaro; T C Jones; E M Carvalho; D Sampaio; S G Reed; A Barral; R Teixeira; W D Johnson
Journal:  J Infect Dis       Date:  1986-12       Impact factor: 5.226

4.  Mononuclear cell subpopulations in human immunodeficiency virus (HIV)-positive versus HIV-negative patients with visceral leishmaniasis.

Authors:  P Cenini; N Berhe; A Hailu; D Frommel
Journal:  J Infect Dis       Date:  1994-03       Impact factor: 5.226

Review 5.  [Leishmaniasis and human immunodeficiency virus infections].

Authors:  J P Dedet; M Lambert; F Pratlong
Journal:  Presse Med       Date:  1995-06-17       Impact factor: 1.228

6.  Visceral leishmaniasis in HIV-1-infected individuals: a common opportunistic infection in Spain?

Authors:  F J Medrano; J Hernández-Quero; E Jiménez; J A Pineda; A Rivero; A Sánchez-Quijano; I D Velez; P Viciana; R Castillo; M J Reyes
Journal:  AIDS       Date:  1992-12       Impact factor: 4.177

7.  HIV-Leishmania co-infections in Italy. Isoenzyme characterization of Leishmania causing visceral leishmaniasis in HIV patients.

Authors:  M Gramiccia; L Gradoni; M Troiani
Journal:  Trans R Soc Trop Med Hyg       Date:  1992 Mar-Apr       Impact factor: 2.184
  7 in total
  6 in total

1.  Mediterranean leishmaniasis in HIV-infected patients: epidemiological, clinical, and diagnostic features of 22 cases.

Authors:  C Agostoni; N Dorigoni; A Malfitano; L Caggese; G Marchetti; S Corona; S Gatti; M Scaglia
Journal:  Infection       Date:  1998 Mar-Apr       Impact factor: 3.553

2.  Optimized PCR using patient blood samples for diagnosis and follow-up of visceral Leishmaniasis, with special reference to AIDS patients.

Authors:  L Lachaud; J Dereure; E Chabbert; J Reynes; J M Mauboussin; E Oziol; J P Dedet; P Bastien
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

Review 3.  Leishmania and human immunodeficiency virus coinfection: the first 10 years.

Authors:  J Alvar; C Cañavate; B Gutiérrez-Solar; M Jiménez; F Laguna; R López-Vélez; R Molina; J Moreno
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

4.  Low sensitivity of peripheral blood smear for diagnosis of subclinical visceral leishmaniasis in human immunodeficiency virus type 1-infected patients.

Authors:  J Delgado; J A Pineda; J Macías; C Regordán; J A Gallardo; M Leal; A Sanchez-Quijano; E Lissen
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

5.  Screening for subclinical Leishmania infection in HIV-infected patients living in eastern Spain.

Authors:  Javier Ena; Francisco Pasquau; María del Mar López-Perezagua; Carmen Martinez-Peinado; Francisco Arjona
Journal:  Pathog Glob Health       Date:  2014-12-02       Impact factor: 2.894

6.  Prevalence of and factors associated with visceral leishmaniasis in human immunodeficiency virus type 1-infected patients in southern Spain.

Authors:  J A Pineda; J A Gallardo; J Macías; J Delgado; C Regordán; F Morillas; F Relimpio; J Martín-Sánchez; A Sánchez-Quijano; M Leal; E Lissen
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.